Should I Buy TARA? TARA 2026 Analysis

Should You Buy Protara Therapeutics Inc (TARA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.000

1 Day change

-2.37%

52 Week Range

7.820

Analysis Updated At

2026/01/26

Protara Therapeutics Inc (TARA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While there are some positive technical indicators, the lack of significant financial performance, absence of recent news or catalysts, and no strong trading signals suggest holding off on buying the stock right now.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 77.754, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is currently trading near its resistance level (R1: 6.018), which may limit further upside in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The stock has bullish moving averages and a positive MACD, indicating upward momentum. Analysts have initiated coverage with an Overweight rating and a $24 price target, suggesting long-term potential.

Neutral/Negative Catalysts

The company has no revenue growth, and its EPS dropped significantly (-38% YoY). There are no recent news catalysts, and the stock has a high implied volatility (148.3), indicating potential risk. Additionally, the stock has a 70% chance of a -9.19% decline over the next month based on historical patterns.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net loss of $13.26M (improved by 18.17% YoY), and a significant EPS decline (-38% YoY). Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Piper Sandler initiated coverage with an Overweight rating and a $24 price target, highlighting the company's potential in unique market opportunities. However, the stock remains under-the-radar and speculative.

6 Analyst Rating

Wall Street analysts forecast TARA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARA is 24.83 USD with a low forecast of 21 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.170

Low

Averages

24.83

High

Current: 7.170

Low

Averages

24.83

High

Piper Sandler

Overweight

initiated

$24

AI Analysis

2026-01-07

Reason

Piper Sandler

Price Target

$24

AI Analysis

2026-01-07

initiated

Overweight

Reason

Piper Sandler initiated coverage of Protara Therapeutics with an Overweight rating and $24 price target. The company is "under-the-radar" despite being a clinical stage biotech with three "potentially substantial and unique market opportunities," the analyst tells investors in a research note.

JonesResearch

Soumit Roy

Buy

initiated

$21

2025-05-22

Reason

JonesResearch

Soumit Roy

Price Target

$21

2025-05-22

initiated

Buy

Reason

JonesResearch analyst Soumit Roy initiated coverage of Protara Therapeutics with a Buy rating and $21 price target. The stock is currently trading at cash value, the analyst tells investors in a research note. The firm says Protara has three diverse, late-stage clinical programs, two of which are "fairly de-risked."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TARA

Unlock Now

TARA Should I Buy

TARA Should I Buy

Should You Buy Protara Therapeutics Inc (TARA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch